I believe that interest in CGT2 from large pharmaceutical companies will increase significantly when we can present positive results from proof-of-concept

Through this agreement with Cobra, we are taking another step closer to clinical studies

With the agreement with Viralgen, CombiGene takes a big step towards having a complete production method in place. The few pieces that are missing to start a large-scale production, we expect to get into place within short. We are thus in a position where we will soon have everything in place to start producing materials for the final preclinical studies, including the toxicology and biodistribution studie.